INCYIncyte CorporationRunning, no new patients
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Diffuse Large B Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 53 (final count)
- Started
- Jul 19, 2022
- Main results expected
- Jul 17, 2024
- Fully finished
- Nov 30, 2027
- Results posted
- Jul 28, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Measured over: up to approximately 2 years
Number of Participants With Any ≥Grade 3 TEAE
Measured over: up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05222555 · record last updated 2026-01-16 · checked 2026-11-09 15:47 UTC